Trifluridine (trifluridine)
Ophthalmic Antivirals Ophthalmic (Eye) Drops
Last reviewed · Source: First Databank (FDB) drug data
Overview
Trifluridine, a fluorinated pyrimidine nucleoside, is an antiviral agent active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and vaccinia virus.
Trifluridine 1% ophthalmic solution is used for the topical treatment of primary keratoconjunctivitis and recurrent epithelial keratitis caused by herpes simplex virus (HSV). Trifluridine 1% ophthalmic solution also is recommended for the topical treatment and prevention of ocular infections caused by vaccinia virus+ that occur as a complication of smallpox vaccination or inadvertent exposure to vaccinia virus in or near the eyes. Safety and efficacy of topical trifluridine for the treatment of ophthalmic infections caused by adenovirus+ have not been established.
Generic name: trifluridine
Pronunciation: (try-FLEWR-ih-deen)
Drug class: Ophthalmic Antivirals
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Trifluridine
Indications
The following indications are listed for Trifluridine:
- Herpes Simplex Keratitis
- Herpes Simplex Keratoconjunctivitis
Also known as: Epithelial Herpes Simplex Keratitis, Herpetic Keratoconjunctivitis, Keratitis Due To Hsv, Keratoconjunctivitis Due To Hsv.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Trifluridine 1% Eye Drops | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route every 4 hourswhile awake following re-epithelialization for an additional 7 days. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Trifluridine 1% Eye Drops | Maintenance | Instill 1 drop into affected eye(s) by ophthalmic route every 4 hourswhile awake following re-epithelialization for an additional 7 days. |
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Epithelial keratopathy
- Keratoconjunctivitis sicca
- Ocular hypertension
- Ocular inflammation
- Ocular itching
- Ocular stromal edema
- Punctate keratitis
More Frequent
- Eyelid edema
- Ocular irritation
Less Frequent
- Conjunctival hyperemia
Precautions
No enhanced messaging available.
No enhanced messaging available.
There are no adequate and well-controlled studies in pregnant women, and trifluridine 1% ophthalmic solution should be used during pregnancy only if potential benefits to the woman justify possible risks to the fetus.
Although trifluridine was not teratogenic at dosages up to 5 mg/kg daily (23 times the estimated human exposure) when given subcutaneously to rats and rabbits, fetal toxicity consisting of delayed ossification of portions of the skeleton was evident at dosage levels of 2.5 and 5 mg/kg daily in rats and 2.5 mg/kg daily in rabbits. In addition, fetal death and resorptions were reported in rabbits at dosages of 2.5 and 5 mg/kg daily. There were no effects in rats or rabbits using subcutaneous trifluridine dosages of 1 mg/kg daily (5 times the estimated human exposure) and there were no teratogenic or fetotoxic effects following topical application of trifluridine 1% ophthalmic solution to the eyes of rabbits (approximately 5 times the estimated human exposure) from days 6-18 of pregnancy. Trifluridine has been shown to be teratogenic when injected directly into the yolk sac of chicken eggs.
It is unlikely that trifluridine is distributed into milk following topical application to the eye because of the relatively small dosage used, dilution in body fluids, and the short half-life of the drug (approximately 12 minutes). However, the drug should not be used in nursing women unless potential benefits to the woman justify possible risks to the infant.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Herpes simplex keratitis | ||
| B00.52 | ICD10CM | Herpesviral keratitis |
| Herpes simplex keratoconjunctivitis | ||
| B00.52 | ICD10CM | Herpesviral keratitis |
| B00.53 | ICD10CM | Herpesviral conjunctivitis |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.